StockNews.AI

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

StockNews.AI • 2 hours

LLYJPMBAC
High Materiality8/10

Information

BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology ...

Original source

AI Summary

Aktis Oncology raised approximately $365.4 million through its IPO, successfully selling 17.65 million shares. The offering, which saw strong demand, solidifies Aktis' position in the targeted radiopharmaceutical sector, setting the stage for future growth and research advancements.

Sentiment Rationale

The strong IPO performance and substantial capital raise are catalysts for positive sentiment surrounding AKTS, reminiscent of other biotech IPO successes. Past IPOs with strong investor backing often lead to upward price movements post-launch.

Trading Thesis

Recommend buying AKTS for long-term growth prospects within oncology innovations.

Market-Moving

  • The IPO's gross proceeds of $365.4 million enhance Aktis' R&D funding.
  • Increased investor interest may lead to a positive stock price momentum.
  • Strong market debut reflects confidence in Aktis' innovative oncology solutions.

Key Facts

  • Aktis closed its IPO, raising $365.4 million.
  • IPO included the sale of 17.65 million shares at $18 each.
  • Underwriters exercised an option to buy an additional 2.65 million shares.
  • Aktis trades under the ticker symbol 'AKTS' starting January 9, 2026.
  • The company focuses on innovative targeted radiopharmaceuticals for oncology.

Companies Mentioned

  • Eli Lilly and Company (LLY): Strategic collaboration with Aktis to develop new radioconjugates.
  • J.P. Morgan (JPM): Acted as a book-running manager for Aktis' successful IPO.
  • BofA Securities (BAC): Jointly managed Aktis' IPO, reflecting strong institutional interest.

Corporate Developments

This news fits the 'Corporate Developments' category as it relates to Aktis' capital-raising efforts through an IPO. The funding will support continued development of its oncology treatments and potentially boost its market position.

Aktis Oncology Closes Upsized Initial Public Offering, Stock Symbol "AKTS"

BOSTON, January 13, 2026 – Aktis Oncology, Inc. (NASDAQ: AKTS), a pioneering clinical-stage oncology company, has successfully closed its upsized initial public offering (IPO) of common stock, further solidifying its position in the targeted radiopharmaceuticals market.

Overview of the IPO

On January 12, 2026, Aktis Oncology announced the completion of its IPO, which consisted of 17,650,000 shares priced at $18.00 per share. Additionally, the underwriters exercised their full option to purchase an extra 2,647,500 shares at the same price, demonstrating strong demand for the company's stock.

The sale of these additional shares is anticipated to conclude on January 14, 2026, contingent upon the fulfillment of standard closing conditions. Overall, the IPO is projected to generate approximately $365.4 million in gross proceeds before deducting underwriting discounts and expenses.

Trading and Underwriters

Aktis’ common stock began trading on the Nasdaq Global Select Market under the ticker symbol AKTS on January 9, 2026. The successful management of the offering was achieved by raising capabilities established by prominent financial institutions including:

  • J.P. Morgan
  • BofA Securities
  • Leerink Partners
  • TD Cowen

SEC Registration and Availability of Prospectus

A registration statement on Form S-1 (File No. 333-292283), as amended, for the offering was filed with the Securities and Exchange Commission (SEC) and was declared effective on January 8, 2026. Investors can obtain copies of the final prospectus through the SEC’s website at www.sec.gov, or directly from the underwriters listed above.

This offering does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction where such an offer would be illegal.

About Aktis Oncology

Aktis Oncology, Inc. is dedicated to advancing the potential of targeted radiopharmaceuticals, aiming to address unmet needs within large patient populations. Its innovative pipeline includes a focus on targeting Nectin-4, utilizing miniprotein radioconjugates to treat various tumor types.

Founded with the expertise from MPM BioImpact, Aktis has developed a proprietary platform designed to deliver the tumor-destroying effects of radioisotopes to affected cells while minimizing side effects. This technology allows for precise treatment with high tumor specificity and rapid clearance from healthy tissues.

Aktis is also engaged in a strategic partnership with Eli Lilly and Company to leverage its platform in the development of new radioconjugates beyond its current projects.

Related News